A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity

Simultaneous targeting of epidermal growth factor receptor (EGFR) and Met in cancer therapy is under pre-clinical and clinical evaluation. Here, we report the finding that treatment with EGFR inhibitors of various tumor cells, when stimulated with hepatocyte growth factor (HGF) and EGF, results in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Castoldi, R, Ecker, V, Wiehle, L, Majety, M, Busl-Schuller, R, Asmussen, M, Nopora, A, Jucknischke, U, Osl, F, Kobold, S, Scheuer, W, Venturi, M, Klein, C, Niederfellner, G, Sustmann, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898114/
https://www.ncbi.nlm.nih.gov/pubmed/23812422
http://dx.doi.org/10.1038/onc.2013.245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898114/
https://www.ncbi.nlm.nih.gov/pubmed/23812422
http://dx.doi.org/10.1038/onc.2013.245

Ejemplares similares